17-Hydroxyprogesterone caproate to prolong pregnancy after preterm rupture of the membranes: early termination of a double-blind, randomized clinical trial

Table 2 Primary outcome and gestational age outcomes

	17-Hydroxyprogesterone Caproate	Placebo
	(N = 4)	(N = 8)
Primary Outcome
Delivery at 34.0 weeks or more	0	0
Delivery at 32.0-33.9 weeks with documented fetal lung maturity	0	0
Gestational Age at Delivery (weeks)	30 ± 4	28 ± 3
Delivery before 32 weeks	2 (50%)	7 (87.5%)
Delivery before 34 weeks	4 (100%)	8 (100%)
Pulmonary Maturity Testing
Immature	1 (25%)	2 (25%)
Not Tested	3 (75%)	6 (75%)
Latency, Randomization to Delivery (weeks)	1.6 ± 1.0	1.3 ± 1.6
Less than 1 week	1 (25%)	5 (62.5%)
1.0 to 1.9 weeks	1 (25%)	1 (12.5%)
2.0 weeks or more	2 (50%)	2 (25%)
Reason for Delivery Before 34 weeks
Spontaneous	0	4 (25%)
Chorioamnionitis	1 (25%)	2 (25%)
Fetal Indications	3 (75%)	2 (25%)

Results expressed as Mean ± SD or N (%).
Fetal indications for delivery included abnormal fetal heart tracings (4 cases) and fetal growth restriction with abnormal umbilical artery Doppler findings (1 case, placebo group).

ISSN: 1756-0500